Cargando…

Update of ALDH as a Potential Biomarker and Therapeutic Target for AML

Studies employing mouse transplantation have illustrated the role of aldehyde dehydrogenase (ALDH) defining hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs). Besides being a molecular marker, ALDH mediates drug resistance in AML, which induces poor prognosis of the patients. In AML pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiangchou, Yao, Rongxin, Wang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817321/ https://www.ncbi.nlm.nih.gov/pubmed/29516013 http://dx.doi.org/10.1155/2018/9192104

Ejemplares similares

The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment
por: Zhang, Hong, et al.
Publicado: (2021)

The rarity of ALDH (+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
por: Hoang, Van T., et al.
Publicado: (2015)

Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
por: Cao, Ziyang, et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors
por: Wei, Yaolu, et al.
Publicado: (2022)

Update on the aldehyde dehydrogenase gene (ALDH) superfamily
por: Jackson, Brian, et al.
Publicado: (2011)

Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
por: di Meo, Nicola Antonio, et al.
Publicado: (2022)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Bone marrow stromal cells induce an ALDH(+) stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway
por: Yuan, Bin, et al.
Publicado: (2020)

A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators
por: Chang, Yi-Cheng, et al.
Publicado: (2023)

Targeting ALDH2 for Therapeutic Interventions in Chronic Pain-Related Myocardial Ischemic Susceptibility
por: Li, Chen, et al.
Publicado: (2018)

An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer
por: Sanchez-Martin, Victoria, et al.
Publicado: (2020)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family
por: Vasiliou, Vasilis, et al.
Publicado: (2005)

Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML
por: Gupta, Kalpana, et al.
Publicado: (2011)

Rational Combinations of Targeted Agents in AML
por: Bose, Prithviraj, et al.
Publicado: (2015)

P450: ALDH1A AS A THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA
por: Shaikh, Mehak, et al.
Publicado: (2023)

Acid ceramidase is upregulated in AML and represents a novel therapeutic target
por: Tan, Su-Fern, et al.
Publicado: (2016)

Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers
por: Qian, Die, et al.
Publicado: (2022)

An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
por: Lin, Shan, et al.
Publicado: (2022)

STAT3 as a potential therapeutic target in ALDH(+) and CD44(+)/CD24(+) stem cell-like pancreatic cancer cells
por: Lin, Li, et al.
Publicado: (2016)

miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target
por: Yamamoto, Haruna, et al.
Publicado: (2016)

Targeting Inflammation by Anthocyanins as the Novel Therapeutic Potential for Chronic Diseases: An Update
por: Kozłowska, Aleksandra, et al.
Publicado: (2021)

Immunomodulation of Interleukin-34 and its Potential Significance as a Disease Biomarker and Therapeutic Target
por: Ge, Yun, et al.
Publicado: (2019)

CircRNAs in colorectal cancer: potential biomarkers and therapeutic targets
por: Zhang, Yuying, et al.
Publicado: (2023)

Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets
por: Favretto, Giane, et al.
Publicado: (2019)

Exosomes: Potential Disease Biomarkers and New Therapeutic Targets
por: Mosquera-Heredia, Maria I., et al.
Publicado: (2021)

MicroRNAs as biomarkers in glaucoma and potential therapeutic targets
por: Martinez, Bridget, et al.
Publicado: (2022)

miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer
por: Chakrabortty, Atonu, et al.
Publicado: (2023)

Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View
por: Schulte, Wibke, et al.
Publicado: (2013)

Non-coding RNA: a potential biomarker and therapeutic target for sepsis
por: Zhang, Tie-Ning, et al.
Publicado: (2017)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

KK-LC-1 as a therapeutic target to eliminate ALDH(+) stem cells in triple negative breast cancer
por: Bu, Jiawen, et al.
Publicado: (2023)

COX-2 as a potential biomarker and therapeutic target in melanoma
por: Tudor, Diana Valentina, et al.
Publicado: (2020)

miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges
por: Zhou, Shan-shan, et al.
Publicado: (2018)

HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
por: Wang, Yanbin, et al.
Publicado: (2019)

Antiviral Therapeutic Potential of Curcumin: An Update
por: Ardebili, Abdollah, et al.
Publicado: (2021)

RNA therapeutics: updates and future potential
por: Zhang, Caroline, et al.
Publicado: (2022)

TRPV2: A Cancer Biomarker and Potential Therapeutic Target
por: Siveen, Kodappully S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_feb9qnevi93csp1uj315plki7i